Updating results

738 results

Sort: Relevance | Date

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance In development

ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Technology appraisal guidance In development

PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Technology appraisal guidance In development

Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Technology appraisal guidance In development

Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Technology appraisal guidance In development

Barrett's oesophagus: ablative therapy

In development [GID-NG10165] Expected publication date: 17 August 2022

NICE guideline In development

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: 18 November 2020

Technology appraisal guidance In development

Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]

In development [GID-TA10584] Expected publication date: TBC

Technology appraisal guidance In development

Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

In development [GID-TA10591] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

In development [GID-TA10592] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-TA10593] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for treated mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma [ID1405]

In development [GID-TA10305] Expected publication date: 16 September 2020

Technology appraisal guidance In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: TBC

Technology appraisal guidance In development

Transcatheter Mitral Valve In Ring (TMVIR) for treating a failing mitral valve repair

In development [GID-IPG10154] Expected publication date: TBC

Interventional procedures guidance In development

Transvaginal laser therapy for urogenital atrophy

In development [GID-IPG10155] Expected publication date: TBC

Interventional procedures guidance In development

Transvaginal laser therapy for stress urinary incontinence

In development [GID-IPG10156] Expected publication date: TBC

Interventional procedures guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Looked-after children and young people

In development [GID-NG10121] Expected publication date: 26 April 2021

NICE guideline In development

Management of gout

In development [GID-NG10151] Expected publication date: 04 April 2022

NICE guideline In development

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]

In development [GID-TA10181] Expected publication date: TBC

Technology appraisal guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: TBC

Technology appraisal guidance In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 26 August 2020

Diagnostics guidance In development

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Avelumab for untreated PD-L1 positive non-small-cell lung cancer [ID1261]

In development [GID-TA10250] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab for multiple myeloma [ID966]

In development [GID-TA10134] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Neonatal parenteral nutrition

In development [GID-QS10087] Expected publication date: 01 February 2021

Quality standard In development

Colorectal cancer (QS update)

In development [GID-QS10141] Expected publication date: 26 January 2021

Quality standard In development

Primary and secondary brain cancers

In development [GID-QS10092] Expected publication date: 26 January 2021

Quality standard In development

Perioperative care

In development [GID-QS10094] Expected publication date: 01 March 2021

Quality standard In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

In development [GID-TA10208] Expected publication date: TBC

Technology appraisal guidance In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 28 May 2021

NICE guideline In development

Postnatal care

In development [GID-NG10070] Expected publication date: 25 November 2020

NICE guideline In development

Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

In development [GID-TA10607] Expected publication date: TBC

Technology appraisal guidance In development

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Technology appraisal guidance In development

Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 19 January 2022

NICE guideline In development

Maintenance of normo-thermia to improve outcomes following neurological injury

In development [GID-IPG10153] Expected publication date: TBC

Interventional procedures guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance In development